GlaxoSmithKline (GSK)
GlaxoSmithKline Valuation (Historical Mult.): 40.02
View GSK Valuation (Historical Mult.) with YCharts Pro.
Access these YCharts Pro features:
Export any data you want
Save any chart as an image
Utilize advanced screener power
View 30 years of financial history
over 90 advanced calculations
Enjoy an advertising free experience
GSK Valuation (Historical Mult.) Rankings
| Overall | 78th percentile | 733 of 3411 |
| Sector | 74th percentile | 79 of 312 in Healthcare |
| Industry | 45th percentile | 6 of 11 in Drug Manufacturers - Major |
GSK Valuation (Historical Mult.) Range, Past 5 Years
| Minimum | 37.24 | Mar 2011 |
| Maximum | 84.82 | Dec 2008 |
| Average | 61.13 |
About Valuation (Historical Mult.)
Valuation (Historical Mult.) is the average of YCharts' individual valuation methods. Since the method is an average, it will tend to be less volatile than either of the individual valuation methods. As a result, we recommend checking the values given by each of the component methods.
If either of the methods is missing for any reason, the fair value is the average of the remaining method.
Learn More
You may also be interested in these GSK related companies
GSK News
@mydanilo It had nothing to do with those news. That was already priced in. Seems like Patent news regarding $TEVA and $GSK was the trigger.
about 6 hours ago by mitrado
about 6 hours ago by mitrado
$AMRN up following news that $Teva and $PRX lost a bid to sell the generic form of $GSK Lovaza. http://stks.co/41F0
about 8 hours ago by abubnic
about 8 hours ago by abubnic
Teva (TEVA), Par Pharma (NPRX) said to lose bid to sell the generic form of Glaxo's (GSK) Lovaza
May 29, 3:20PM Street Insider
May 29, 3:20PM Street Insider
$GSK reacts to $HGSI poison pill. Stubborn, or what? It seems they do not want to get pushed or pulled.
about 7 days ago by OysterX
about 7 days ago by OysterX
GlaxoSmithKline Amends HGS Tender Offer to Address Poison Pill, Requires HGS to Redeem Pill
May 23, 8:37AM Benzinga
May 23, 8:37AM Benzinga
Canaccord Genuity maintains a 'Buy' on Auxilium Pharmaceuticals (AUXL); Bumping Guidance on Testim Partnership with GSK
May 22, 8:42AM Street Insider
May 22, 8:42AM Street Insider
Auxilium Pharma (AUXL), Glaxo (GSK) Enter Testim 1% Co-Promotion Agreement
May 21, 7:03AM Street Insider
May 21, 7:03AM Street Insider
Glaxo (GSK) Comments on Human Genome (HGSI) Bid Rejection; Will Continue with $13/Share Tender
May 17, 1:17PM Street Insider
May 17, 1:17PM Street Insider
Still think that $GSK will not succeed with $HGSI takeover at 13/share. They will increase the offer price, but probably not above 15.
about 13 days ago by OysterX
about 13 days ago by OysterX
News related to $GSK, currently 0.0% since open: 'Prestige Brands posts small fiscal 4Q loss' http://stks.co/3s9V
about 13 days ago by TradeBot
about 13 days ago by TradeBot
Human Genome Sciences (HGSI) Unanimously Rejects GlaxoSmithKline (GSK) Offer
May 17, 7:06AM Street Insider
May 17, 7:06AM Street Insider
$GSK Trametinib also in the spotlight at ASCO '12 with six presentations over 4 days. http://stks.co/3roL
about 13 days ago by abubnic
about 13 days ago by abubnic
$GSK Dabrafenib getting its share of attention at ASCO '12 with 50 presentations over 4 days. http://stks.co/3roI
about 13 days ago by abubnic
about 13 days ago by abubnic
$PFE $LLY $GSK So this is the condition some drug commercials warned us about! And we thought they were kidding. http://stks.co/3q2n
about 14 days ago by laughing_stock
about 14 days ago by laughing_stock
Don't see $XNPT popping 100% like $ARNA did, not as glamorous and still has to settle with $GSK. They would get 10 million if still partnrd
about 14 days ago by Glopolon
about 14 days ago by Glopolon
Barclays Maintains an 'Equalweight' on Human Genome Sciences (HGSI); Looking At $15/Share For GSK To Seal The Deal
May 14, 3:58PM Street Insider
May 14, 3:58PM Street Insider
$XNPT, No Debt, Drug has already been approved for RLS, so safety issues known. Court case with $GSK still out there, want settlement.
about 18 days ago by Glopolon
about 18 days ago by Glopolon
RT @JasonMilano8 $AMRN Here is a news about current CEO of Amarin selling his former company Reliant to ($GSK) in 2007: http://stks.co/3k0G
about 21 days ago by JasonMilano8
about 21 days ago by JasonMilano8
Breakfast Links | via @PointsnFigures http://stks.co/3jto $AMZN $GSK $HGSI $ZNGA
about 21 days ago by STNet
about 21 days ago by STNet
That's a surprise. $GSK goes hostile with $HGSI offer at 13. Did not expect that and am curious whether HGSI has something up its sleeve.
about 21 days ago by OysterX
about 21 days ago by OysterX
$AMRN Here is a news about current CEO of Amarin selling his former company Reliant to GlaxoSmithKline ($GSK) in 2007: http://stks.co/3jYt
about 21 days ago by JasonMilano8
about 21 days ago by JasonMilano8
$XNPT, Only non-dopaminergic option for RLS, is the advantage over generics. If $XNPT can work things out with $GSK, this should be $5+
about 21 days ago by Glopolon
about 21 days ago by Glopolon
Huf Post: Two Drugs Harness Immune System To Fight Cancer. http://stks.co/3iDa $DNDN $BMY $AZN $ONTY $GSK
about 22 days ago by abubnic
about 22 days ago by abubnic
$XNPT Sounds like Astellas is going to be better partner than $GSK, Hope they can work things out with $GSK re: Horizant.
about 23 days ago by Glopolon
about 23 days ago by Glopolon
$XNPT $GSK, FDA PDUFA date June 9th for Horizant treating postherpetic neuralgia. Horizant already approved in Japan for restless leg synd.
about 26 days ago by Glopolon
about 26 days ago by Glopolon
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| GSK | 44.38 | +0.10 | +0.23% | 111.75B |
| GSIT | 4.18 | -0.02 | -0.48% | 120.25M |
| GSIG | 11.98 | +0.13 | +1.10% | 397.09M |
| GSI | 0.9874 | +0.12 | +13.48% | |
| GSH | 16.41 | +0.11 | +0.67% | 2.314B |
| GSB | 2.06 | -0.09 | -4.19% | 39.15M |
| GSAT | 0.391 | -0.01 | -3.43% | 120.61M |
| GS | 97.82 | +1.12 | +1.16% | 47.86B |
| GRZ | 3.40 | +0.11 | +3.34% | 195.89M |
| GRX | 8.14 | +0.04 | +0.49% |